港股異動丨德琪醫藥-B升超14% 股價創4個月新高 年內累升超7成!
德琪醫藥-B(6996.HK)今日盤中一度升超14%至1.12港元,股價創去年10月14日以來約4個月新高,今年以來已累升超72%,遠遠跑贏大盤表現(同期恒指累升約13%)。德琪醫藥昨日晚間發公吿稱,希維奧®(塞利尼索)(與硼替佐米和地塞米松(XVd)聯用,用於治療既往接受過至少兩種治療的復發╱難治性多發性骨髓瘤(rrMM)成年患者)已在台灣獲批納入全民健康保險。自2025年3月1日起,希維奧®將獲正式納入台灣《全民健康保險用藥品項表》。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.